Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer

Yuan,Peng; Xu,Benling; Wang,Chengzheng; Zhang,Chengjuan; Sun,Miaomiao; Yuan,Long

doi:10.3892/ol.2016.4199

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer

Authors:
- Peng Yuan
- Benling Xu
- Chengzheng Wang
- Chengjuan Zhang
- Miaomiao Sun
- Long Yuan
View Affiliations

Affiliations: Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
Published online on: February 8, 2016 https://doi.org/10.3892/ol.2016.4199
Pages: 2101-2105
Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine Ki-67 expression in tissue of luminal type breast cancer and to investigate the association between the Ki-67 expression level and clinicopathology of breast cancer. A total of 62 patients with breast cancer were included in the study group, whereas 30 patients undergoing a health check‑up who were diagnosed with breast hyperplasia were included in the control group. Levels of Ki‑67 expression in patients of the two groups were assessed using fluorescent quantitative polymerase chain reaction. The association between Ki‑67 and the clinicopathology of the cancer was investigated by analyzing cancer cell proliferation and migration by reducing Ki-67 expression in the human MCF‑7 cancer cell line. Compared with the controls, Ki‑67 expression was significantly increased in the serum and cancer tissue of breast cancer patients (P<0.05). Ki‑67 mRNA expression was significantly higher in cancer tissue than that in the corresponding paracancerous tissue of breast cancer (P<0.05). In addition, a high expression of Ki‑67 was positively correlated with the clinical staging of tumor, tumor size and lymphatic metastasis of breast cancer, with statistical significance (P<0.05). In MCF‑7 cells with a reduced Ki‑67 expression, the proliferation activity and migration of breast cancer cells were significantly reduced (P<0.05). In conclusion, Ki‑67 may be involved in promoting the genesis and development of breast cancer by affecting the proliferation and migration of cancer cells.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Karuturi M, VanderWalde N and Muss H: Approach and management of breast cancer in the elderly. Clin Geriatr Med. 32:133–153. 2016. View Article : Google Scholar : PubMed/NCBI
3	Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ and Loi S: Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. Dec 15–2015.doi: 10.1038. View Article : Google Scholar : PubMed/NCBI
4	Sun Z, Shi Y, Shen Y, Cao L, Zhang W and Guan X: Analysis of different HER-2 mutations in breast cancer progression and drug resistance. J Cell Mol Med. 19:2691–2701. 2015. View Article : Google Scholar : PubMed/NCBI
5	Kim DK, Kim DW, Kim SW, Kim DY, Lee CH and Rhee CS: Ki67 antigen as a predictive factor for prognosis of sinonasal mucosal melanoma. Clin Exp Otorhinolaryngol. 1:206–210. 2008. View Article : Google Scholar : PubMed/NCBI
6	Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 29:4273–4278. 2011. View Article : Google Scholar : PubMed/NCBI
7	Krüger K, Stefansson IM, Collett K, Arnes JB, Aas T and Akslen LA: Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast. 22:282–288. 2013. View Article : Google Scholar : PubMed/NCBI
8	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Panel members: Strategies for subtypes - dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z and Cao X: MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol. 183:2150–2158. 2009. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Cintra JR, Teixeira MT, Diniz RW, Gonçalves Junior H, Florentino TM, Freitas GF, Oliveira LR, Neves MT, Pereira T and Guerra MR: Immunohistochemical profile and clinical-pathological variables in breast cancer. Rev Assoc Med Bras. 58:178–187. 2012. View Article : Google Scholar : PubMed/NCBI
12	Xiao ZS, Li Y, Guan YL and Li JG: GSTT1 polymorphism and breast cancer risk in the Chinese population: an updated meta-analysis and review. Int J Clin Exp Med. 8:6650–6657. 2015.PubMed/NCBI
13	Hong W and Dong E: The past, present and future of breast cancer research in China. Cancer Lett. 51:1–5. 2014. View Article : Google Scholar
14	Arjonen A, Kaukonen R, Mattila E, Rouhi P, Högnäs G, Sihto H, Miller BW, Morton JP, Bucher E, Taimen P, et al: Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. J Clin Invest. 124:1069–1082. 2014. View Article : Google Scholar : PubMed/NCBI
15	Macpherson IR, Rainero E, Mitchell LE, van den Berghe PV, Speirs C, Dozynkiewicz MA, Chaudhary S, Kalna G, Edwards J, Timpson P, et al: CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. J Cell Sci. 127:3893–3901. 2014. View Article : Google Scholar : PubMed/NCBI
16	Beresford MJ, Wilson GD and Makris A: Measuring proliferation in breast cancer: Practicalities and applications. Breast Cancer Res. 8:2162006. View Article : Google Scholar : PubMed/NCBI
17	Miller HC, Drymousis P, Flora R, Goldin R, Spalding D and Frilling A: Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg. 38:1353–1361. 2014. View Article : Google Scholar : PubMed/NCBI
18	Rademakers SE, Hoogsteen IJ, Rijken PF, Terhaard CH, Doornaert PA, Langendijk JA, van den Ende P, van der Kogel AJ, Bussink J and Kaanders JH: Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial. Head Neck. 37:171–176. 2015. View Article : Google Scholar : PubMed/NCBI
19	Warth A, Cortis J, Soltermann A, Meister M, Budczies J, Stenzinger A, Goeppert B, Thomas M, Herth FJ, Schirmacher P, et al: Tumour cell proliferation (Ki-67) in non-small cell lung cancer: A critical reappraisal of its prognostic role. Br J Cancer. 111:1222–1229. 2014. View Article : Google Scholar : PubMed/NCBI
20	Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M III, Shipley WU, et al: Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 22:2133–2140. 2004. View Article : Google Scholar : PubMed/NCBI
21	Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, et al: MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol. 27:3177–3184. 2009. View Article : Google Scholar : PubMed/NCBI
22	Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M and Ortmann O: Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 139:539–552. 2013. View Article : Google Scholar : PubMed/NCBI
23	Zheng Z, Li HZ and Li YQ: Prognostic factors and associated models for metastatic renal cell carcinoma treated with targeted therapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 36:450–453. 2014.(In Chinese). PubMed/NCBI
24	Pichu S, Krishnamoorthy S, Shishkov A, Zhang B, McCue P and Ponnappa BC: Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition. PLoS One. 7:e485672012. View Article : Google Scholar : PubMed/NCBI